197 companies

Pfizer

Market Cap: US$137.0b

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

PFE

US$23.60

7D

-2.3%

1Y

-18.5%

Merck

Market Cap: US$199.0b

Operates as a healthcare company worldwide.

MRK

US$77.60

7D

-4.8%

1Y

-31.4%

Johnson & Johnson

Market Cap: US$425.5b

Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.

JNJ

US$177.73

7D

2.0%

1Y

10.1%

Bristol-Myers Squibb

Market Cap: US$89.9b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY

US$43.41

7D

-4.8%

1Y

-13.4%

Amgen

Market Cap: US$150.3b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

AMGN

US$271.18

7D

-1.7%

1Y

-15.0%

Gilead Sciences

Market Cap: US$141.0b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD

US$110.99

7D

-2.3%

1Y

33.7%

Perrigo

Market Cap: US$2.9b

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.

PRGO

US$20.76

7D

-2.9%

1Y

-19.0%

AbbVie

Market Cap: US$388.6b

A research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.

ABBV

US$218.54

7D

-1.6%

1Y

13.9%

Phibro Animal Health

Market Cap: US$1.6b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

PAHC

US$38.04

7D

-6.2%

1Y

72.1%

Agilent Technologies

Market Cap: US$35.3b

Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

A

US$121.89

7D

-4.5%

1Y

-16.9%

Zoetis

Market Cap: US$62.8b

Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally.

ZTS

US$141.13

7D

-4.1%

1Y

-27.6%

Viatris

Market Cap: US$11.3b

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

VTRS

US$9.49

7D

-3.8%

1Y

-18.3%

Qiagen

Market Cap: US$9.8b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

QGEN

US$43.93

7D

-4.0%

1Y

-5.1%

Royalty Pharma

Market Cap: US$20.9b

Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

RPRX

US$34.90

7D

-2.3%

1Y

23.8%

Eli Lilly

Market Cap: US$666.0b

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

LLY

US$714.59

7D

-6.3%

1Y

-21.4%

Organon

Market Cap: US$2.7b

Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.

OGN

US$10.12

7D

-6.7%

1Y

-47.2%

Halozyme Therapeutics

Market Cap: US$8.8b

A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.

HALO

US$73.97

7D

-3.5%

1Y

29.9%

Atai Life Sciences

Market Cap: US$1.2b

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

ATAI

US$5.17

7D

9.5%

1Y

334.5%

Avantor

Market Cap: US$8.2b

Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

AVTR

US$11.78

7D

-8.4%

1Y

-54.8%

Intellia Therapeutics

Market Cap: US$1.9b

A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.

NTLA

US$16.61

7D

3.1%

1Y

-19.3%

TG Therapeutics

Market Cap: US$5.2b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

TGTX

US$34.64

7D

6.2%

1Y

48.5%

Tourmaline Bio

Market Cap: US$1.2b

Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.

TRML

US$47.72

7D

0.06%

1Y

92.0%

Corcept Therapeutics

Market Cap: US$8.8b

Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

CORT

US$82.73

7D

3.7%

1Y

91.2%

Centessa Pharmaceuticals

Market Cap: US$3.2b

A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.

CNTA

US$23.01

7D

0.2%

1Y

46.8%

Axsome Therapeutics

Market Cap: US$5.9b

A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

AXSM

US$116.01

7D

-2.2%

1Y

29.4%

Trevi Therapeutics

Market Cap: US$1.0b

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.

New

TRVI

US$8.48

7D

-0.7%

1Y

169.2%

Tilray Brands

Market Cap: US$1.4b

A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.

TLRY

US$1.19

7D

-5.6%

1Y

-31.6%

Biogen

Market Cap: US$20.2b

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

BIIB

US$135.67

7D

-5.7%

1Y

-29.9%

LENZ Therapeutics

Market Cap: US$1.2b

Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

LENZ

US$40.03

7D

-4.0%

1Y

79.9%

BioNTech

Market Cap: US$24.0b

A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

BNTX

US$98.08

7D

1.8%

1Y

-16.6%

Alnylam Pharmaceuticals

Market Cap: US$60.1b

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

ALNY

US$449.58

7D

-0.6%

1Y

63.7%

Travere Therapeutics

Market Cap: US$2.2b

A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

TVTX

US$24.61

7D

1.7%

1Y

63.6%

Arcus Biosciences

Market Cap: US$1.3b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

RCUS

US$12.37

7D

-0.6%

1Y

-19.6%

BioLife Solutions

Market Cap: US$1.2b

Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

BLFS

US$24.18

7D

-8.0%

1Y

0.04%

Madrigal Pharmaceuticals

Market Cap: US$9.5b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

MDGL

US$422.99

7D

-4.0%

1Y

97.8%

Exelixis

Market Cap: US$10.5b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

EXEL

US$38.69

7D

-4.4%

1Y

47.4%

Page 1 of 6